Asia Pacific Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4) and By Country - Trends, Analysis and Forecast till 2034
收藏www.prophecymarketinsights.com2024-07-01 更新2025-01-21 收录
下载链接：
https://www.prophecymarketinsights.com/market_insight/asia-pacific-cell-and-gene-therapy-cdmo-market-5421
下载链接
链接失效反馈官方服务：
资源简介：
Asia pacific cell and gene therapy cdmo market size and share is estimated to be USD 11.3 Billion by 2034, with a CAGR of 29.20% during the forecast period. Some of key market players Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc.
亚太地区细胞和基因治疗合同研发组织（CDMO）市场规模预计到2034年将达到113亿美元，在预测期内，年复合增长率（CAGR）将达到29.20%。其中，一些主要市场参与者包括Catalent Inc.、LONZA GROUP、RECIPHARM AB、无锡先进疗法公司、Pfizer CentreOne以及Charles River Laboratories International Inc.
提供机构：
Prophecy Market Insights
